Artiva Stops Lead Drug Candidate Development After Two Patient Deaths
Artiva Biotherapeutics stopped development of its lead drug candidate after two patient deaths during a clinical trial. ARTV shares fell 32%, heading for their worst session since April 2025.
Shares of Artiva Biotherapeutics (ARTV) crashed 32% on Tuesday, heading for their worst session since April 2025, after the company stopped the development of its lead drug candidate following two patient deaths during a clinical trial.At the time of writing, ARTV shares traded near eight-month low…